Continuing Education Activity

Metoclopramide is a dopamine receptor antagonist and has been approved by the FDA to treat nausea and vomiting in patients with gastroesophageal reflux disease or diabetic gastroparesis by increasing gastric motility. It is also used to control nausea and vomiting in chemotherapy patients. Additionally, metoclopramide can be administered prophylactically to prevent nausea and vomiting in postoperative patients when nasogastric suction is contraindicated or unavailable and has shown surprising success in treating migraines; however, the FDA has not explicitly approved it for these other conditions. This activity will highlight the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of metoclopramide, pertinent for interprofessional team members in treating patients with conditions that are of clinical value.

Objectives:

• Explain the mechanisms of action of metoclopramide.
• Identify the approved and off-label indications for metoclopramide.
• Review the potential adverse events associated with metoclopramide.
• Summarize the contraindications to therapy with metoclopramide.

Indications

The FDA has approved metoclopramide to treat nausea and vomiting in patients with gastroesophageal reflux disease (in patients who fail to respond to established therapy) and diabetic gastroparesis by increasing gastric motility.[1][2] Parenteral metoclopramide is also FDA approved to control nausea and vomiting in chemotherapy patients.[3][4]

Metoclopramide is used off-label prophylactically to prevent nausea and vomiting in postoperative patients when nasogastric suction is contraindicated or unavailable. It is particularly useful in this role because it does not cause any concomitant increase in gastric secretions.[5] Metoclopramide is also used off-label to treat acute migraine in the emergency department. It is an effective adjunctive agent for acute nausea and vomiting and reduces headache intensity; hence it is a valuable agent for the short-term treatment of acute migraine in the ED. It is important to recognize that FDA has not explicitly approved it for acute migraine. Still, it is a valuable alternative to opioids due to the potential for opioid use disorder.[6][7]

Metoclopramide can also be used off-label to treat hyperemesis gravidarum in pregnant patients; still, it should be used cautiously because of the lack of studies on the effects of the drug in pregnant women.[8][9] Recent studies have also shown evidence of metoclopramide’s efficacy in treating Diamond Blackfan syndrome.[10][11] Metoclopramide has also been efficacious in treating nausea in critically ill advanced liver disease patients.[12]

Mechanism of Action

Metoclopramide works by antagonizing central and peripheral dopamine-two receptors (D2) in the medullary chemoreceptor trigger zone in the area postrema, usually stimulated by levodopa or apomorphine. It achieves this by decreasing the sensitivity of visceral afferent nerves that transmit from the gastrointestinal system to the vomiting center in the area postrema in the chemoreceptor trigger zone.[13] In addition to antagonizing dopamine receptors, metoclopramide is an antagonist at 5HT3 (type 3 serotonin receptors) and an agonist at 5HT4 receptors.[14][15] Metoclopramide also blocks the antiperistaltic effects of apomorphine, allowing metoclopramide to slow apomorphine's inhibition of gastric emptying, thereby accelerating gastric emptying by increasing the amplitude and duration of esophageal contractions. Consequently, it increases the resting tone of the lower esophageal sphincter while simultaneously relaxing the duodenal bulb and pyloric sphincter, thereby increasing the peristalsis of the duodenum and jejunum.[16][17]

Pharmacokinetics

Absorption: Metoclopramide is rapidly and well absorbed from the gastrointestinal tract, and peak plasma concentrations are attained about 1 to 2 hours after the oral dose. Metoclopramide is lipid-soluble, giving it a large half-life and a large volume of distribution. Its half-life can range from 4.5 hours to 8.8 hours.[18]

Distribution: The volume of distribution is high (approximately 3.5 L/kg), which suggests the extensive distribution of drugs to the tissues.[19]

Metabolism: Metoclopramide is metabolized by oxidation primarily via cytochrome P450 2D6 (CYP2D6), glucuronide, and sulfate conjugation.[20]

Excretion: In a study, approximately 85% of the radioactivity of an orally administered dose is recovered in the urine, and half of it is present as a parent or conjugated metoclopramide. Around 18–22% of the dose is recovered as free metoclopramide in urine. Metoclopramide's elimination half-life in adults with normal renal function has been reported to be ~ 6 hours. In adults with severe renal impairment, there is a reduced metoclopramide clearance, increasing the elimination half-life (7.7 to 17.8 hours).[14]

Administration

Metoclopramide is generally administered orally in a tablet or solution form. The dosage of the tablets and solutions is generally 5 to 10 mg. It is usually taken before meals and before sleep. However, it can be administered intramuscularly or intravenously in severely nauseous patients; the intravenous route takes effect much more quickly.[13] Parenteral metoclopramide is also 5 mg. Rectal administration is also an option, as is an intraperitoneal injection in patients undergoing peritoneal dialysis.[21] The USFDA also approved metoclopramide nasal spray for symptomatic relief in adults with acute and recurrent diabetic gastroparesis. The nasal formulation has a unique benefit; it can be absorbed without depending on the absorption in the state of gastroparesis, thus ensuring the delivery of a therapeutic dose of metoclopramide.[22]

Metoclopramide dosing for various indications is as follows:

Diabetic Gastroparesis: 10 mg orally/IV/IM four times daily for a maximum duration of 12 weeks; max dose is 40 mg daily. Start at 5 mg four times daily for geriatric patients. For patients who are poor CYP2D6 metabolizers, give 5 mg four times daily (30 minutes before meals and at bedtime) with a max dose of 20 mg daily.[2]

GERD (chronic): 10 to 15 mg orally/IM/IV four times daily for a maximum duration of 12 weeks; maximum dose of 60 mg daily. Start at 5 mg four times daily for geriatric patients; max dose 30 mg daily. For patients who are poor CYP2D6 metabolizers, give 5 mg four times daily (30 minutes before meals and at bedtime) or 10 mg three times daily (30 minutes before meals).

GERD (intermittent): Up to 20 mg orally/IV/IM for one dose before symptoms begin.

Prophylaxis of Chemotherapy-related Nausea and Vomiting: 1 to 2 mg/kg/dose IV every 2 to 3 hours; the first dose is given 30 minutes before starting chemotherapy, then repeated for two doses every 2 hours, then three doses every 3 hours. Pretreat with diphenhydramine to reduce extrapyramidal symptoms. Metoclopramide is not a first-line agent for this purpose.

Use in Specific Patient Populations

Patients with Hepatic Impairment: Reduce the dose of metoclopramide in patients with moderate or severe hepatic impairment (Child-Pugh B or C). The recommended dose for diabetic gastroparesis is 5 mg four times daily.

Patients with Renal Impairment: In patients with kidney failure, it is generally recommended that metoclopramide maintenance doses be reduced to avoid drug accumulation.[23] Use caution in moderate or severe renal impairment (creatinine clearance<60 mL/minute). In patients with end-stage renal disease requiring hemodialysis, the maximum recommended dose is 5 mg twice daily. Lifestyle modification in the form of smaller and more frequent meals is first-line therapy. According to the American society of nephrology guidelines, metoclopramide can be used at 2.5 mg every four hours in refractory cases.[24]

Pregnancy Considerations: Metoclopramide can cross the placental barrier. Maternal administration of metoclopramide during delivery can lead to extrapyramidal signs and methemoglobinemia in neonates. According to ACOG(The American College of Obstetricians and Gynecologists) guidelines, metoclopramide should be used only in refractory cases of nausea and vomiting during pregnancy, 5 to 10 mg every 6 to 8 hours, orally or intramuscularly, in adequately hydrated patients. The preferred pharmacological management is pyridoxine(vitamin B6) or pyridoxine in combination with doxylamine.[25]

Breastfeeding Considerations: Metoclopramide is used as a galactagogue, but the clinical value of metoclopramide in increasing milk supply is uncertain. A meta-analysis of eight clinical trials indicated that metoclopramide increased serum prolactin but did not increase milk supply. Metoclopramide use increases the risk of postpartum depression and tardive dyskinesia. Use with caution.[26]

Adverse Effects

Adverse effects of metoclopramide use include extrapyramidal symptoms.[27][28] These include the following:

• Acute dystonic reactions

  • Torticollis
  • Trismus
  • Opisthotonus
  • Akathisia
  • Dystonia
  • Oculogyric crisis
  • Laryngospasm
  • Hyperprolactinemia
  • Tardive dyskinesia
  • Parkinson symptoms
  • Neuroleptic malignant syndrome 

Neuroleptic malignant syndrome is a rare adverse effect.[29] It is among the most serious adverse reactions because it manifests as follows:

• Hyperthermia
• Lead pipe rigidity
• Leukocytosis
• Elevated creatine phosphokinase levels
• Altered consciousness
• Symptoms of autonomic instability (potentially) 

• Diaphoresis
• Tachycardia
• Incontinence
• Pallor
• Irregular blood pressure or pulse
• Cardiac arrhythmias

Thus, any patient on metoclopramide who develops neuroleptic malignant syndrome should have metoclopramide immediately discontinued and undergo treatment with dantrolene. These adverse effects stem from metoclopramide’s anti-dopaminergic mechanism of action. It is important to note that these adverse effects are dose-independent and generally reversible following discontinuation of the drug.[30] Furthermore, it is important to keep in mind that oculogyric crises caused by metoclopramide can resemble the following:

• Seizures
• Cranial nerve palsies
• Paroxysmal tonic upward gaze
• Encephalopathy[31]

Metoclopramide-induced hyperprolactinemia can cause the following:

• Gynecomastia
• Galactorrhea
• Amenorrhea
• Impotence
• Hypogonadism

In patients with glucose-6-phosphate dehydrogenase deficiency or nicotinamide adenine dinucleotide cytochrome b5 reductase deficiency, metoclopramide can cause methemoglobinemia and sulfhemoglobinemia.[32][33] Additionally, metoclopramide can increase serum aldosterone levels, potentially causing fluid retention and volume overload. Therefore, it must be used with caution in patients with heart failure or cirrhosis of the liver.[34] Metoclopramide has also been shown to cause a non-thrombocytopenic purpuric rash that subsides upon discontinuation of the drug.[35]

Less acute adverse effects of metoclopramide, generally reversible and observed in children, include the following:

• Sedation 
• Diarrhea[36]

Rarer psychiatric side effects that have developed following brief exposure to metoclopramide include:

• Panic disorder
• Major depressive disorder
• Agoraphobia[37]

Drug-Drug Interactions

Reduced efficacy of dopamine agonists(like bromocriptine and cabergoline)[38] Furthermore, metoclopramide can increase serum aspirin levels by increasing the absorption of aspirin, potentially causing salicylate toxicity.[39] In addition to increasing the absorption of aspirin, metoclopramide can also increase serum levels of bupropion and its metabolite hydroxybupropion because it aids gastric emptying and thus bupropion absorption in the small intestine.[40] This can increase the serum levels of other drugs, given that bupropion and hydroxybupropion, in turn, inhibit the effects of the CYP2D6 metabolic enzyme.[41] 

Concurrent administration of metoclopramide and antipsychotic drugs should be avoided due to the potential for additive effects and neuroleptic malignant syndrome(NMS).[42] Metoclopramide should not be administered with CYP2D6 inhibitors like fluoxetine as there is an increased risk of extrapyramidal symptoms.[43]

Contraindications

Metoclopramide is contraindicated in patients with the following:

• Known hypersensitivity to metoclopramide or excipients[44]
• Gastrointestinal bleeding 
• Obstruction 
• Perforation[30]

Other contraindications include the following:

• Pheochromocytoma
• Seizures
• Depression
• Parkinson disease

Metoclopramide is contraindicated in patients with depression because it can cause major depressive disorder.[37] It is contraindicated in patients with seizures because it lowers the seizure threshold and can result in longer and more frequent seizures.[45] It is contraindicated in patients with depression and Parkinson disease because of the aforementioned adverse effects of major depressive disorder and parkinsonian symptoms. It is contraindicated in pheochromocytoma because it releases catecholamines and can exacerbate pheochromocytoma, causing a hypertensive crisis, which can be treated with phentolamine.[46][45]

US Boxed Warning: Metoclopramide can cause tardive dyskinesia, a serious movement disorder. Tardive dyskinesia risk increases with the total treatment duration and total cumulative exposure. Therefore, avoid treatment with metoclopramide tablets for longer than 12 weeks. Discontinue metoclopramide in patients who develop clinical signs or symptoms of tardive dyskinesia. In some patients, symptoms may decrease or resolve after metoclopramide is discontinued.[47][48]

Monitoring

It is also important to note that the efficacy of metoclopramide can be diminished if the patient takes anticholinergics or narcotic analgesic medications because these drugs decrease the gastric emptying rate.[49] Metoclopramide decreases the absorption rate of drugs generally absorbed from the stomach, like digoxin, while increasing the absorption of drugs absorbed from the small intestine, like cyclosporine.[50][51]

Metoclopramide is included in the KIDS list (Key Potentially Inappropriate Drugs in Pediatrics), a reference tool to identify medications associated with a high risk for adverse drug reactions. Monitor when metoclopramide is used in pediatric patients.[52] Metocloclopramide is also recognized as a potentially inappropriate medication for older adults per the American Geriatrics Society 2019 updated Beers criteria. Monitor elderly patients for extrapyramidal symptoms and tardive dyskinesia.[53]

Toxicity

The following are the primary symptoms of metoclopramide overdose:

• Sedation[54]
• Diarrhea[55]
• Extrapyramidal adverse effects (particularly tardive dyskinesia)[27]

Tardive dyskinesia is an adverse effect, often seen in antipsychotic medications, that generally manifests as grimacing, lip-smacking, tongue flicking, and general choreoathetoid movements of the body.[56] Because it can sometimes be irreversible, it is the most threatening potential complication of metoclopramide overdose, and metoclopramide treatment should be discontinued in any patient who develops tardive dyskinesia. Extrapyramidal adverse effects have been observed in metoclopramide overdose, particularly in infants and the elderly, who are at the most significant risk.[57] Retrospective analysis has shown that pediatric emergency room visits leading to extrapyramidal symptoms can be caused by metoclopramide syrup overdose.[58]

Though there is no specific treatment for metoclopramide overdose, its extrapyramidal effects are among the most common adverse effects. They can be alleviated with anticholinergics like benztropine and antihistamines like diphenhydramine.[59] Supportive therapy is recommended, while dialysis is generally ineffective in treating metoclopramide overdose.[23]

Enhancing Healthcare Team Outcomes

Metoclopramide is widely used in most hospitals and is an effective drug for gastroparesis and postoperative nausea and vomiting. However, the drug does have several side effects that all healthcare practitioners must be familiar with, so an interprofessional team approach is necessary. The nurse and pharmacist are in a prime position to monitor the drug and, hopefully, reduce its adverse effects by closely monitoring the patient and recommending discontinuation when symptoms arise. Of all the side effects, the most concerning are the extrapyramidal reactions that are more likely to occur in diabetics, children, seniors, and those already taking antipsychotic medications. The risk of developing tardive dyskinesia from metoclopramide varies from 1 to 15%, and the condition is quite debilitating. Hence, before using this drug, the nurse, pharmacist, and prescriber should obtain informed consent from the patient. All patients should be told about the potential for developing dyskinesias before treatment. If the patient has an adverse risk profile, the pharmacist should offer another agent option to the prescriber for consideration.

All interprofessional team members are also responsible for communicating concerns with other team members. They must also maintain accurate and updated records of their observations and interventions with the patient so that all team members have the most recent data on the case. Closely monitoring the patient is critical, and the interprofessional team, including clinicians, nursing, and pharmacy, will drive optimal outcomes.[60] [Level 5]

Outcomes

Metoclopramide has proven valuable in managing diabetic gastroparesis, postoperative nausea, and vomiting. However, the potential risk for dyskinesias has led to a re-evaluation of this agent. Experts indicate that metoclopramide should be started with the lowest possible dose and the shortest duration of time. The drug is effective in the short term, but its CNS adverse drug reactions are worrisome.[61] [Level 5]

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Rettura F, Bronzini F, Campigotto M, Lambiase C, Pancetti A, Berti G, Marchi S, de Bortoli N, Zerbib F, Savarino E, Bellini M. Refractory Gastroesophageal Reflux Disease: A Management Update. Front Med (Lausanne). 2021;8:765061. [PMC free article: PMC8591082] [PubMed: 34790683]

2.

Shakhatreh M, Jehangir A, Malik Z, Parkman HP. Metoclopramide for the treatment of diabetic gastroparesis. Expert Rev Gastroenterol Hepatol. 2019 Aug;13(8):711-721. [PubMed: 31314613]

3.

Adel N. Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies. Am J Manag Care. 2017 Sep;23(14 Suppl):S259-S265. [PubMed: 28978206]

4.

Flank J, Robinson PD, Holdsworth M, Phillips R, Portwine C, Gibson P, Maan C, Stefin N, Sung L, Dupuis LL. Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children With Cancer. Pediatr Blood Cancer. 2016 Jul;63(7):1144-51. [PubMed: 26960036]

5.

De Oliveira GS, Castro-Alves LJ, Chang R, Yaghmour E, McCarthy RJ. Systemic metoclopramide to prevent postoperative nausea and vomiting: a meta-analysis without Fujii's studies. Br J Anaesth. 2012 Nov;109(5):688-97. [PubMed: 23015617]

6.

Najjar M, Hall T, Estupinan B. Metoclopramide for Acute Migraine Treatment in the Emergency Department: An Effective Alternative to Opioids. Cureus. 2017 Apr 20;9(4):e1181. [PMC free article: PMC5438233] [PubMed: 28533997]

7.

Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, Pozo-Rosich P, Martelletti P, Ducros A, Lantéri-Minet M, Braschinsky M, Del Rio MS, Daniel O, Özge A, Mammadbayli A, Arons M, Skorobogatykh K, Romanenko V, Terwindt GM, Paemeleire K, Sacco S, Reuter U, Lampl C, Schytz HW, Katsarava Z, Steiner TJ, Ashina M. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-514. [PMC free article: PMC8321897] [PubMed: 34145431]

8.

Tan PC, Khine PP, Vallikkannu N, Omar SZ. Promethazine compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. Obstet Gynecol. 2010 May;115(5):975-981. [PubMed: 20410771]

9.

Abas MN, Tan PC, Azmi N, Omar SZ. Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. Obstet Gynecol. 2014 Jun;123(6):1272-1279. [PubMed: 24807340]

10.

Akiyama M, Yanagisawa T, Yuza Y, Yokoi K, Ariga M, Fujisawa K, Hoshi Y, Eto Y. Successful treatment of Diamond-Blackfan anemia with metoclopramide. Am J Hematol. 2005 Apr;78(4):295-8. [PubMed: 15795909]

11.

Bartels M, Bierings M. How I manage children with Diamond-Blackfan anaemia. Br J Haematol. 2019 Jan;184(2):123-133. [PMC free article: PMC6587714] [PubMed: 30515771]

12.

Vijayaraghavan R, Maiwall R, Arora V, Choudhary A, Benjamin J, Aggarwal P, Jamwal KD, Kumar G, Joshi YK, Sarin SK. Reversal of Feed Intolerance by Prokinetics Improves Survival in Critically Ill Cirrhosis Patients. Dig Dis Sci. 2022 Aug;67(8):4223-4233. [PMC free article: PMC8364303] [PubMed: 34392492]

13.

Lee A, Kuo B. Metoclopramide in the treatment of diabetic gastroparesis. Expert Rev Endocrinol Metab. 2010;5(5):653-662. [PMC free article: PMC3027056] [PubMed: 21278804]

14.

Ge S, Mendley SR, Gerhart JG, Melloni C, Hornik CP, Sullivan JE, Atz A, Delmore P, Tremoulet A, Harper B, Payne E, Lin S, Erinjeri J, Cohen-Wolkowiez M, Gonzalez D., Best Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee. Population Pharmacokinetics of Metoclopramide in Infants, Children, and Adolescents. Clin Transl Sci. 2020 Nov;13(6):1189-1198. [PMC free article: PMC7719387] [PubMed: 32324313]

15.

Sanger GJ, Andrews PLR. A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research. Front Pharmacol. 2018;9:913. [PMC free article: PMC6131675] [PubMed: 30233361]

16.

Ramsbottom N, Hunt JN. Studies of the effect of metoclopramide and apomorphine on gastric emptying and secretion in man. Gut. 1970 Dec;11(12):989-93. [PMC free article: PMC1553172] [PubMed: 5511820]

17.

Harada T, Hirosawa T, Morinaga K, Shimizu T. Metoclopramide-induced Serotonin Syndrome. Intern Med. 2017;56(6):737-739. [PMC free article: PMC5410491] [PubMed: 28321081]

18.

McGovern EM, Grevel J, Bryson SM. Pharmacokinetics of high-dose metoclopramide in cancer patients. Clin Pharmacokinet. 1986 Nov-Dec;11(6):415-24. [PubMed: 3542335]

19.

Bauer M, Barna S, Blaickner M, Prosenz K, Bamminger K, Pichler V, Tournier N, Hacker M, Zeitlinger M, Karanikas G, Langer O. Human Biodistribution and Radiation Dosimetry of the P-Glycoprotein Radiotracer [¹¹C]Metoclopramide. Mol Imaging Biol. 2021 Apr;23(2):180-185. [PMC free article: PMC7910245] [PubMed: 33481175]

20.

Chua EW, Harger SP, Kennedy MA. Metoclopramide-Induced Acute Dystonic Reactions May Be Associated With the CYP2D6 Poor Metabolizer Status and Pregnancy-Related Hormonal Changes. Front Pharmacol. 2019;10:931. [PMC free article: PMC6713716] [PubMed: 31507424]

21.

Trapnell BC, Mavko LE, Birskovich LM, Falko JM. Metoclopramide suppositories in the treatment of diabetic gastroparesis. Arch Intern Med. 1986 Nov;146(11):2278-9. [PubMed: 3778059]

22.

Gajendran M, Sarosiek I, McCallum R. Metoclopramide nasal spray for management of symptoms of acute and recurrent diabetic gastroparesis in adults. Expert Rev Endocrinol Metab. 2021 Mar;16(2):25-35. [PubMed: 33739209]

23.

Lehmann CR, Heironimus JD, Collins CB, O'Neil TJ, Pierson WP, Crowe JT, Melikian AP, Wright GJ. Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis. Clin Pharmacol Ther. 1985 Mar;37(3):284-9. [PubMed: 3971652]

24.

Davison SN, Tupala B, Wasylynuk BA, Siu V, Sinnarajah A, Triscott J. Recommendations for the Care of Patients Receiving Conservative Kidney Management: Focus on Management of CKD and Symptoms. Clin J Am Soc Nephrol. 2019 Apr 05;14(4):626-634. [PMC free article: PMC6450361] [PubMed: 30819670]

25.

Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 189: Nausea And Vomiting Of Pregnancy. Obstet Gynecol. 2018 Jan;131(1):e15-e30. [PubMed: 29266076]

26.

Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Jan 15, 2025. Metoclopramide. [PubMed: 30000411]

27.

Moos DD, Hansen DJ. Metoclopramide and extrapyramidal symptoms: a case report. J Perianesth Nurs. 2008 Oct;23(5):292-9. [PubMed: 18926476]

28.

Donnet A, Harle JR, Dumont JC, Alif Cherif A. Neuroleptic malignant syndrome induced by metoclopramide. Biomed Pharmacother. 1991;45(10):461-2. [PubMed: 1820178]

29.

Gupta S, Nihalani ND. Neuroleptic Malignant Syndrome: A Primary Care Perspective. Prim Care Companion J Clin Psychiatry. 2004;6(5):191-194. [PMC free article: PMC518983] [PubMed: 15514687]

30.

Ponte CD, Nappi JM. Review of a new gastrointestinal drug--metoclopramide. Am J Hosp Pharm. 1981 Jun;38(6):829-33. [PubMed: 7018232]

31.

Koban Y, Ekinci M, Cagatay HH, Yazar Z. Oculogyric crisis in a patient taking metoclopramide. Clin Ophthalmol. 2014;8:567-9. [PMC free article: PMC3964159] [PubMed: 24672222]

32.

Mary AM, Bhupalam L. Metoclopramide-induced methemoglobinemia in an adult. J Ky Med Assoc. 2000 Jun;98(6):245-7. [PubMed: 10870338]

33.

Tanishima K, Tanimoto K, Tomoda A, Mawatari K, Matsukawa S, Yoneyama Y, Ohkuwa H, Takazakura E. Hereditary methemoglobinemia due to cytochrome b5 reductase deficiency in blood cells without associated neurologic and mental disorders. Blood. 1985 Dec;66(6):1288-91. [PubMed: 4063522]

34.

Nagahama S, Fujimaki M, Kawabe H, Nakamura R, Saito I, Saruta T. Effect of metoclopramide on the secretion of aldosterone and other adrenocortical steroids. Clin Endocrinol (Oxf). 1983 Mar;18(3):287-93. [PubMed: 6861367]

35.

Upputuri S, Prasad S. Metoclopramide-induced delayed non-thrombocytopenic purpuric rash. Clin Drug Investig. 2006;26(12):745-7. [PubMed: 17274681]

36.

Lau Moon Lin M, Robinson PD, Flank J, Sung L, Dupuis LL. The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis. Drug Saf. 2016 Jul;39(7):675-87. [PubMed: 27003816]

37.

Anfinson TJ. Akathisia, panic, agoraphobia, and major depression following brief exposure to metoclopramide. Psychopharmacol Bull. 2002 Winter;36(1):82-93. [PubMed: 12397849]

38.

Torre DL, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag. 2007 Oct;3(5):929-51. [PMC free article: PMC2376090] [PubMed: 18473017]

39.

Volans GN. The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol. 1975 Feb;2(1):57-63. [PMC free article: PMC1402484] [PubMed: 791318]

40.

Lai AA, Schroeder DH. Clinical pharmacokinetics of bupropion: a review. J Clin Psychiatry. 1983 May;44(5 Pt 2):82-4. [PubMed: 6406470]

41.

Joy MS, Frye RF, Stubbert K, Brouwer KR, Falk RJ, Kharasch ED. Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. J Clin Pharmacol. 2010 Jun;50(6):714-20. [PMC free article: PMC3614080] [PubMed: 20103693]

42.

Mazhar F, Akram S, Haider N, Ahmed R. Overlapping of Serotonin Syndrome with Neuroleptic Malignant Syndrome due to Linezolid-Fluoxetine and Olanzapine-Metoclopramide Interactions: A Case Report of Two Serious Adverse Drug Effects Caused by Medication Reconciliation Failure on Hospital Admission. Case Rep Med. 2016;2016:7128909. [PMC free article: PMC4940515] [PubMed: 27433163]

43.

Igata R, Hori H, Atake K, Katsuki A, Nakamura J. Adding metoclopramide to paroxetine induced extrapyramidal symptoms and hyperprolactinemia in a depressed woman: a case report. Neuropsychiatr Dis Treat. 2016;12:2279-81. [PMC free article: PMC5012626] [PubMed: 27621638]

44.

Pietrzko P, Zakrzewski A, Matuszewski T, Kruszewski J. Angioneurotic edema: a rare case of hypersensitivity to metoclopramide. Postepy Dermatol Alergol. 2013 Apr;30(2):117-8. [PMC free article: PMC3834686] [PubMed: 24278059]

45.

Weinstein RB, Fife D, Sloan S, Voss EA, Treem W. Prevalence of Chronic Metoclopramide Use and Associated Diagnoses in the US Pediatric Population. Paediatr Drugs. 2015 Aug;17(4):331-7. [PMC free article: PMC4516863] [PubMed: 26014368]

46.

Guillemot J, Compagnon P, Cartier D, Thouennon E, Bastard C, Lihrmann I, Pichon P, Thuillez C, Plouin PF, Bertherat J, Anouar Y, Kuhn JM, Yon L, Lefebvre H. Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5-HT4) receptors. Endocr Relat Cancer. 2009 Mar;16(1):281-90. [PubMed: 18948374]

47.

Xu D, Ham AG, Tivis RD, Caylor ML, Tao A, Flynn ST, Economen PJ, Dang HK, Johnson RW, Culbertson VL. MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia. EBioMedicine. 2017 Dec;26:132-137. [PMC free article: PMC5832625] [PubMed: 29191560]

48.

Avalos DJ, Sarosiek I, Loganathan P, McCallum RW. Diabetic gastroparesis: current challenges and future prospects. Clin Exp Gastroenterol. 2018;11:347-363. [PMC free article: PMC6165730] [PubMed: 30310300]

49.

Nimmo WS. Drugs, diseases and altered gastric emptying. Clin Pharmacokinet. 1976;1(3):189-203. [PubMed: 797497]

50.

Johnson BF, Bustrack JA, Urbach DR, Hull JH, Marwaha R. Effect of metoclopramide on digoxin absorption from tablets and capsules. Clin Pharmacol Ther. 1984 Dec;36(6):724-30. [PubMed: 6499354]

51.

Wadhwa NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplant Proc. 1987 Feb;19(1 Pt 2):1730-3. [PubMed: 3547879]

52.

Meyers RS, Thackray J, Matson KL, McPherson C, Lubsch L, Hellinga RC, Hoff DS. Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List. J Pediatr Pharmacol Ther. 2020;25(3):175-191. [PMC free article: PMC7134587] [PubMed: 32265601]

53.

By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019 Apr;67(4):674-694. [PubMed: 30693946]

54.

Gralla RJ. Metoclopramide. A review of antiemetic trials. Drugs. 1983 Feb;25 Suppl 1:63-73. [PubMed: 6682376]

55.

Sewell DD, Jeste DV. Metoclopramide-associated tardive dyskinesia. An analysis of 67 cases. Arch Fam Med. 1992 Nov;1(2):271-8. [PubMed: 1341603]

56.

Casey DE. Tardive dyskinesia. West J Med. 1990 Nov;153(5):535-41. [PMC free article: PMC1002605] [PubMed: 1979705]

57.

Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. Br Med J (Clin Res Ed). 1985 Oct 05;291(6500):930-2. [PMC free article: PMC1417247] [PubMed: 3929968]

58.

Chang MY, Lin KL, Wang HS, Wu CT. Drug-Induced Extrapyramidal Symptoms at the Pediatric Emergency Department. Pediatr Emerg Care. 2020 Oct;36(10):468-472. [PubMed: 31790070]

59.

Pringsheim T, Doja A, Belanger S, Patten S., Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) guideline group. Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. Paediatr Child Health. 2011 Nov;16(9):590-8. [PMC free article: PMC3223903] [PubMed: 23115503]

60.

Fog AF, Kvalvaag G, Engedal K, Straand J. Drug-related problems and changes in drug utilization after medication reviews in nursing homes in Oslo, Norway. Scand J Prim Health Care. 2017 Dec;35(4):329-335. [PMC free article: PMC5730030] [PubMed: 29096573]

61.

Sridharan K, Sivaramakrishnan G. Interventions for treating nausea and vomiting in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. Expert Rev Clin Pharmacol. 2018 Nov;11(11):1143-1150. [PubMed: 30261764]

Disclosure: Sasank Isola declares no relevant financial relationships with ineligible companies.

Disclosure: Azhar Hussain declares no relevant financial relationships with ineligible companies.

Disclosure: Anterpreet Dua declares no relevant financial relationships with ineligible companies.

Disclosure: Karampal Singh declares no relevant financial relationships with ineligible companies.

Disclosure: Ninos Adams declares no relevant financial relationships with ineligible companies.